Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Urinary DNA Methylation Testing (Bladder EpiCheck®) and Its Peri-operative Kinetics for the Prediction of Residual Disease at Second Transurethral Resection in T1 Non-muscle-invasive Bladder Cancer (EPIRE)

13 de noviembre de 2026 actualizado por: Istituto Oncologico Veneto IRCCS

Urinary DNA Methylation Testing (Bladder EpiCheck®) and Its Peri-operative Kinetics for the Prediction of Residual Disease at Second Transurethral Resection in T1 Non-muscle-invasive Bladder Cancer The EPIRE Study

European Association of Urology (EAU) guidelines mandate a second transurethral resection of bladder tumour (re-TURBt) for patients with high-grade or pT1 non-muscle-invasive bladder cancer (NMIBC) to eradicate residual disease and avoid understaging. However, 30% to 50% or more of patients undergoing re-TURBt have no residual tumour found upon re-resection, incurring surgical and anaesthetic risks, potential morbidity, healthcare costs, and delays in adjuvant therapy without direct oncological benefit.

Current non-invasive triage tools, such as urine cytology and office cystoscopy, suffer from low sensitivity or diagnostic ambiguity due to ongoing post-operative inflammation and tissue healing in a recently resected bladder. While novel molecular biomarkers like Bladder EpiCheck® demonstrate high sensitivity and negative predictive value in the surveillance setting, single-timepoint measurements shortly after resection struggle to differentiate transient, healing-induced epigenetic changes from true persistent malignancy.

Evaluating the longitudinal trajectory of the EpiScore across two distinct post-operative timepoints (T1 and T2) provides a physiological basis for distinguishing decaying inflammatory/reparative signals from stable or rising signals indicative of residual disease. Demonstrating the diagnostic accuracy of Bladder EpiCheck® at T2, alongside the dynamic change in EpiScore (ΔEpiScore), will establish whether non-invasive urine biomarker testing can reliably select low-risk pT1 NMIBC patients in whom re-TURBt can be safely omitted.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

60

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 99 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • age ≥18 years;
  • histologically confirmed pT1 urothelial carcinoma of the bladder (any grade, WHO 2022 and 1973 classifications) on the definitive histology of the initial TURBt;
  • macroscopically complete initial resection as reported by the surgeon, with detrusor muscle present in the specimen, both formally documented in the operative and pathology records;
  • indication for second TURBt according to EAU guidelines, with the procedure scheduled at the study centre and expected within ten weeks of the initial TURBt;
  • clinically localised non-metastatic disease (cN0, cM0);
  • patients able to provide written informed consent.
  • Previous BCG treatment is allowed.

Exclusion Criteria:

  • muscle-invasive disease (≥pT2) on the definitive histology of the initial TURBt;
  • initial resection judged incomplete by the operating surgeon - whether because visible tumour was deliberately left behind or because the procedure had to be curtailed and a planned second look arranged - or absence of detrusor muscle in the specimen - these patients receive second TURBt per guidelines but are outside the study question, which concerns the completely resected patient;
  • pure non-urothelial histology (primary adenocarcinoma, pure squamous cell carcinoma, small cell neuroendocrine carcinoma, sarcoma). Variant histologies of urothelial carcinoma are not an exclusion criterion but are recorded as a covariate;
  • concomitant upper tract urothelial carcinoma, or a history of it within the preceding 24 months, given the documented positivity of Bladder EpiCheck® in that disease [19];
  • A single early post-operative chemotherapy instillation, where given, is not an exclusion criterion but is recorded as a covariate;
  • previous pelvic radiotherapy;
  • indwelling urinary catheter or intermittent self-catheterisation; urinary diversion or neobladder;
  • clinically non-localised disease (cN+, cM+);
  • pregnancy or breastfeeding;
  • TURBt performed in an emergency setting for uncontrolled bleeding or other life-threatening indication, in which resection quality cannot be assured;
  • second TURBt not performed at the study centre, with consequent unavailability of the reference standard;
  • patients unable to provide written informed consent, or any condition that in the investigator's judgement compromises the ability to comply with study procedures.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Diagnóstico
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: EPIRE

The investigational IVD medical device evaluated as the index test is the Bladder EpiCheck® system (manufactured by Nucleix Ltd.; exclusive Italian distributor: A. Menarini Diagnostics s.r.l.). The assay is CE-IVD marked under Directive 98/79/EC (Annex III, General IVD category) and cleared by the US FDA via the 510(k) pathway. The manufacturer operates under a certified UNI CEI EN ISO 13485:2016 quality management system. Bladder EpiCheck® profiles the DNA methylation patterns of 15 proprietary DNA biomarkers on genomic DNA isolated from the cellular pellet of a voided urine sample. The assay protocol involves DNA extraction, digestion with a methylation-sensitive restriction enzyme, and subsequent multiplex real-time polymerase chain reaction (multiplex real-time PCR).

Dedicated analysis software generates a quantitative integrative score termed the EpiScore, on a continuous scale from 0 to 100. In accordance with the manufacturer's Instructions for Use (IFU), the qualitative diagno

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Diagnostic accuracy of Bladder EpiCheck® test at timepoint T2 for residual disease at second TURBt in T1 NMIBC patients.
Periodo de tiempo: Through study completion, an average of 2 years

Diagnostic accuracy of EpiScore at T2 (categorized as > 60 positive vs ≤ 60 negative) evaluated against central histopathology review of the second TURBt, measured as Sensitivity, Specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV), Accuracy, and Likelihood Ratios.

Through study completion, an average of 2 years
Diagnostic accuracy of change EpiScore between the two subsequent timepoints T1 and T2.
Periodo de tiempo: Through study completion, an average of 2 years

Average daily rate of change in EpiScore, calculated as ∆EpiScore=(T2-T1)/(Days between T1 and T2) evaluated against second TURBt residual disease status using a univariate logistic regression model and Area Under the ROC Curve (AUC) with 95% CI.

Through study completion, an average of 2 years

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Diagnostic accuracy of Bladder EpiCheck® test at timepoint T1
Periodo de tiempo: Through study completion, an average of 2 years

Sensitivity, Specificity, PPV, NPV, Accuracy, and Likelihood Ratios (95% CI) of EpiScore at T1 (> 60 vs ≤ 60) for residual disease at second TURBt

Through study completion, an average of 2 years
Diagnostic accuracy of urinary cytology at timepoints T1 and T2
Periodo de tiempo: Through study completion, an average of 2 years

Sensitivity, Specificity, PPV, NPV, Accuracy, and Likelihood Ratios (95% CI) of urinary cytology (Paris System classification) at T1 and T2 against second TURBt histopathology

Through study completion, an average of 2 years
Agreement at T1 and T2 between Bladder EpiCheck® and urinary cytology
Periodo de tiempo: Through study completion, an average of 2 years

Concordance between Bladder EpiCheck® and urinary cytology at T1 and T2, quantified by Cohen's kappa (κ) coefficient.

Through study completion, an average of 2 years
Agreement between T1 and T2 of Bladder EpiCheck®;
Periodo de tiempo: Through study completion, an average of 2 years

Agreement on paired aliquots of Bladder EpiCheck® between timepoints T1 and T2 with McNemar's test for paired data

Through study completion, an average of 2 years
Agreement between T1 and T2 of urinary cytology
Periodo de tiempo: Through study completion, an average of 2 years

Agreement on paired aliquots of urinary cytology between timepoints T1 and T2 with McNemar's test for paired data

Through study completion, an average of 2 years
Diagnostic accuracy at T1 and T2 of the combination of Bladder EpiCheck® and urinary cytology, defined in two versions: (1) as negative when both are negative, (2) as negative when at least one is negative
Periodo de tiempo: Through study completion, an average of 2 years

Sensitivity, Specificity, PPV, NPV, and Accuracy at T1 and T2 evaluated under two combination definitions: (1) negative when both tests are negative; (2) negative when at least one test is negative

Through study completion, an average of 2 years
Diagnostic accuracy in the previous settings for predicting high-grade disease, ≥ pT1, and/or concomitant Carcinoma in Situ (CIS) at second TURBt;
Periodo de tiempo: Through study completion, an average of 2 years

Diagnostic accuracy measures (Sensitivity, Specificity, PPV, NPV) of tests and combinations specifically for predicting high-grade disease, ≥ pT1, and/or concomitant Carcinoma in Situ (CIS) at second TURBt

Through study completion, an average of 2 years
Diagnostic accuracy of alternative definitions of change in EpiScore
Periodo de tiempo: Through study completion, an average of 2 years

Diagnostic accuracy and AUC for alternative definitions of Episcore change between T1 and T2: absolute difference (T2-T1) and relative percentage change (T2-T1)/T1;

Through study completion, an average of 2 years
Change in positivity rate of Bladder EpiCheck® and urinary cytology between T1 and T2 among patients whose second TURBt is negative.
Periodo de tiempo: Through study completion, an average of 2 years

9) Proportion of test positivity change between T1 and T2 in patients without residual disease (measuring the clearance rate of post-operative false positives).

Through study completion, an average of 2 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

31 de enero de 2027

Finalización primaria (Estimado)

31 de enero de 2029

Finalización del estudio (Estimado)

31 de enero de 2029

Fechas de registro del estudio

Enviado por primera vez

13 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

13 de noviembre de 2026

Publicado por primera vez (Actual)

19 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

13 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • IOV-NMIBC-02-2026-EPIRE

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .